Jacobs, Maartje S <br/><br/>
Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation.  [electronic resource] 

 -  The European journal of health economics : HEPAC : health economics in prevention and care  Sep 2018 
 - 957-965 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1618-7601 
<br/><br/><label>Standard No.: </label>10.1007/s10198-017-0942-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Atrial Fibrillation--therapy<br/>Cost-Benefit Analysis<br/>Electric Countershock<br/>Factor Xa Inhibitors--economics<br/>Humans<br/>Netherlands<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Rivaroxaban--economics<br/>Stroke--prevention & control